Abstract
Background: Renin-angiotensin system (RAS) and its main product Angiotensin II (AngII) are in the focus of the pharmacological industry mainly because of hypertension treatment. Up-regulated RAS is generally associated with cardiovascular diseases and consequent organs injuries. The classic inhibition of RAS is based on the blocking of the type 1 AngII receptors and inhibition of ACE. The concept of the circulating and tissue RAS opens new challenges for the drug targeting. In spite of a big effort invested, in some cases a traditional RAS manipulation is struggling with unwanted side effects and/or resistance to treatment.
Objective: To improve the efficiency of the classic RAS inhibitors specific complications issuing from feed-back circuits inside the RAS have to be elucidated. Moreover, new peptidases identified in the AngII biosynthesis and Angiotensin 1-7/MAS pathways with opposing effects to AngII are tested for the clinical use. The aim of this review is also to bring attention to new tools in RAS manipulation based on the RNA interference (RNAi). RNAi employs small non-coding nucleic acids that interfere with the mRNA translation. The usefulness of this approach has been demonstrated in the treatment of oncological diseases and progress was also made in the field of the cardiovascular medicine.
Conclusion: We suppose that in the near future, in addition to traditional pharmacological tools, RNAi will contribute to the control of RAS and AngII production. RNAi may also be of importance in the manipulation of tissue RAS that is not easily accessible by the traditional chemical substances.
Keywords: siRNA, miRNA, silencing, RNAi, angiotensinogen, renin, ACE, Alamandine.
Current Medicinal Chemistry
Title:Angiotensin II in the Human Physiology: Novel Ways for Synthetic Compounds Utilization
Volume: 23 Issue: 42
Author(s): Iveta Herichová
Affiliation:
Keywords: siRNA, miRNA, silencing, RNAi, angiotensinogen, renin, ACE, Alamandine.
Abstract: Background: Renin-angiotensin system (RAS) and its main product Angiotensin II (AngII) are in the focus of the pharmacological industry mainly because of hypertension treatment. Up-regulated RAS is generally associated with cardiovascular diseases and consequent organs injuries. The classic inhibition of RAS is based on the blocking of the type 1 AngII receptors and inhibition of ACE. The concept of the circulating and tissue RAS opens new challenges for the drug targeting. In spite of a big effort invested, in some cases a traditional RAS manipulation is struggling with unwanted side effects and/or resistance to treatment.
Objective: To improve the efficiency of the classic RAS inhibitors specific complications issuing from feed-back circuits inside the RAS have to be elucidated. Moreover, new peptidases identified in the AngII biosynthesis and Angiotensin 1-7/MAS pathways with opposing effects to AngII are tested for the clinical use. The aim of this review is also to bring attention to new tools in RAS manipulation based on the RNA interference (RNAi). RNAi employs small non-coding nucleic acids that interfere with the mRNA translation. The usefulness of this approach has been demonstrated in the treatment of oncological diseases and progress was also made in the field of the cardiovascular medicine.
Conclusion: We suppose that in the near future, in addition to traditional pharmacological tools, RNAi will contribute to the control of RAS and AngII production. RNAi may also be of importance in the manipulation of tissue RAS that is not easily accessible by the traditional chemical substances.
Export Options
About this article
Cite this article as:
Herichová Iveta, Angiotensin II in the Human Physiology: Novel Ways for Synthetic Compounds Utilization, Current Medicinal Chemistry 2016; 23 (42) . https://dx.doi.org/10.2174/0929867323666161014144552
DOI https://dx.doi.org/10.2174/0929867323666161014144552 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology A Review of Epidemiological Evidence on Short-Term Effects of Environmental Factors on Respiratory Problems in Children
Current Respiratory Medicine Reviews Difference in Blood Pressure Measurements Between Arms: Methodological and Clinical Implications
Current Pharmaceutical Design Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Parathyroid Carcinoma Causing Mild Hyperparathyroidism in Neurofibromatosis Type 1: A Case Report and Systematic Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Involvement of Orexigenic Peptides in the Mechanism of Gastric Mucosal Integrity and Healing of Chronic Gastric Ulcers
Current Pharmaceutical Design Killer Beacons for Combined Cancer Imaging and Therapy
Current Medicinal Chemistry Acute Fulminant Hepatatis in Kidney Transplant Recipient After Repeated Sevoflurane Anesthesia - A Case Report and Literature Review
Current Drug Safety The Ignored Role of Intraoperative Hypotension in Producing Postoperative Acute Kidney Injury-An Obligatory Appeal for More Preventative Nephrology
Current Hypertension Reviews Effect of Honey & Olive Oil Supplemented Bio-Yoghurt Feeding on Lipid Profile, Blood Glucose and Hematological Parameters in Rats
Current Nutrition & Food Science Hair Growth: Focus on Herbal Therapeutic Agent
Current Drug Discovery Technologies Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs)
Recent Patents on Anti-Cancer Drug Discovery In Vivo Transdermal Delivery of Leuprolide Using Microneedles and Iontophoresis
Current Pharmaceutical Biotechnology Pharmacogenetics of Irinotecan
Current Medicinal Chemistry - Anti-Cancer Agents Water-in-Oil Microemulsions for Protein Delivery: Loading Optimization and Stability
Current Pharmaceutical Biotechnology Selar (<i>Selar crumenophthalmus</i>) Fish Protein Hydrolysate Has Antidiabetic Properties Possibly through GLP-1
Current Nutrition & Food Science Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Modeling the Interactions Between α1-Adrenergic Receptors and Their Antagonists
Current Computer-Aided Drug Design Patent Selections :
Recent Patents on CNS Drug Discovery (Discontinued) Prostate Cancer Molecular Background: The IGF-1Ec Story
Clinical Cancer Drugs